MILAN - Genenta Science (NASDAQ:GNTA), a clinical-stage biotech company with a market capitalization of $61.84 million, and Anemocyte announced Friday a strategic collaboration focused on ...

The Viral Vector and Plasmid DNA Manufacturing Market refers to the industrial processes and services that enable the production of viral vectors and plasmid DNA used in gene therapies, vaccine ...

CORALVILLE, Iowa (March 27, 2024)—Global genomics solutions provider Integrated DNA Technologies (IDT) is expanding its gene synthesis offerings with a new custom vector onboarding tool. The ...

The number of viral vector-based gene therapies in clinical trials has recently grown into the thousands due to the tremendous genetic disease-curing potential they harbor. Yet the comprehensive ...

Ottawa, Feb. 19, 2025 (GLOBE NEWSWIRE) -- The global viral vector and plasmid DNA manufacturing market size was valued at USD 7.19 billion in 2024 and is expected to be worth around USD 46.02 billion ...

DNA vectors play an important role in gene therapy, serving as the vehicles that deliver genetic material into cells. While plasmid DNA (pDNA) is traditionally used, it has drawbacks that can limit ...

Sarepta Therapeutics SRPT announced that the FDA has granted platform-technology designation to its viral vector rAAVrh74, used in the investigational gene therapy SRP-9003. This therapy is being ...